대동맥 장골 폐쇄성 질환 치료 시장 규모, 점유율, 동향 분석 보고서 : 디바이스 유형별, 시술별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Aorto-iliac Occlusive Disease Treatment Market Size & Trends:

The global aorto-iliac occlusive disease treatment market size was estimated at USD 2.26 billion in 2025 and is projected to reach USD 3.36 billion by 2033, growing at a CAGR of 5.02% from 2026 to 2033. Aorto-Iliac Occlusive Disease (AIOD) is a condition where the large arteries in the abdomen and pelvis, specifically the aorta and iliac arteries, become narrowed or blocked, reducing blood flow to the legs.

The increasing prevalence of Peripheral Artery Disease (PAD) is one of the key factors driving the market's growth. According to the American Heart Association, Inc. article published in June 2023, Peripheral artery disease (PAD) affects an estimated 200 million people worldwide. It significantly contributes to developing Aorto-iliac Occlusive Disease (AIOD). The growing prevalence of PAD, driven by factors such as aging populations, diabetes, and smoking, has increased the need for effective treatments for AIOD. This rising demand drives the adoption of minimally invasive procedures, including iliac artery stenting and endovascular therapies, which help restore proper blood flow and alleviate symptoms like leg pain and limited mobility.

Increasing government initiatives drive the growth of the market. According to the Congress.Gov article published in June 2023, the U.S. government took a significant step toward enhancing early detection and management of Peripheral Artery Disease (PAD), a primary contributor to Aorto-Iliac Occlusive Disease, through the introduction of the Arterial and Venous Comprehensive (ARC) Act. This legislation proposes amendments to the Social Security Act, aiming to ensure that Medicare and Medicaid beneficiaries identified as high-risk can access PAD screening without incurring out-of-pocket costs. Covered diagnostic procedures include ankle-brachial index (ABI) tests and arterial duplex scans, critical for identifying PAD and assessing disease severity in the aorto-iliac region. Authorizing USD 6 million in annual funding from 2024 to 2028, the ARC Act seeks to improve early diagnosis and timely intervention, potentially reducing the burden of advanced occlusive conditions and boosting the demand for targeted treatment options such as iliac stenting and revascularization therapies. This initiative promotes preventive care and supports broader access to essential vascular health services.

Moreover, as per the American College of Cardiology Foundation. article published in February 2025, the Sustainable Cardiopulmonary Rehabilitation Services in the Home Act (H.R. 783), recently reintroduced, proposes to make the Medicare coverage for in-home cardiopulmonary rehabilitation services permanent. This legislative move is designed to enhance access to essential rehabilitation, especially for patients with mobility limitations or those residing in remote areas. Facilitating easier access to rehabilitation care, this initiative supports the effective management of peripheral artery disease (PAD) and related conditions, including Aorto-Iliac Occlusive Disease, ultimately improving patient outcomes and driving demand for advanced treatment options in the market.

Technological advancements in aorto-iliac occlusive disease (iliac disease) treatment drive the market's growth. For instance, in January 2025, Bentley Medical introduced the BeFlow iliac covered stent system at the Leipzig Interventional Course (LINC) 2025, marking a significant advancement in treating aorto-iliac occlusive disease. Designed to address complex iliac lesions, the BeFlow stent offers enhanced long-term patency and durability, aligning with European Society for Vascular Surgery guidelines that recommend covered stents for heavily stenosed or occluded iliac arteries. Available in diameters ranging from 7 to 10 mm and lengths of 37 and 57 mm, the BeFlow stent aims to provide a cost-effective alternative to bare metal stents, improving patient access to advanced vascular interventions.

Global Aorto-iliac Occlusive Disease Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional & country levels and analyzes the industry trends in each sub-segment from 2021 to 2033. for this study, Grand View Research has segmented the global aorto-iliac occlusive disease treatment market report based on device type, procedure, end use, and region:

• Device Type Outlook (Revenue, USD Million, 2021 - 2033)
• Endovascular Devices
  • Balloon Angioplasty Devices
  • Atherectomy Systems
  • Stents
  • Self-Expanding Stents
  • Balloon-Expandable Stents
  • Covered Stent Grafts
  • Bifurcated Aortic Stent Grafts
• Surgical Devices
• Procedure Outlook (Revenue, USD Million, 2021 - 2033)
• Endovascular Procedures
  • Balloon Angioplasty
  • Primary Stenting
  • Kissing Stents
  • Covered Stent Grafts
  • Endovascular Aortic Repair (EVAR)
• Hybrid Procedures
• Open Surgical Procedures
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Outpatient Facilities
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Device Type
  • 1.2.2. Procedure
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Device Type Segment
  • 2.2.2. Procedure Segment
  • 2.2.3. End Use Segment
  • 2.2.4. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of PAD
    • 3.2.1.2. Rising government initiatives
    • 3.2.1.3. Technological advancements
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with the devices and procedures
    • 3.2.2.2. Lack of awareness and early diagnosis in rural regions
• 3.3. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Estimates & Trend Analysis

• 4.1. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Dashboard
• 4.2. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Movement Analysis
• 4.3. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Size & Forecasts and Trend Analysis, by Device Type, 2021 to 2033 (USD Million)
• 4.4. Endovascular Devices
  • 4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 4.4.2. Balloon Angioplasty Devices Market estimates and forecast 2021 to 2033 (USD Million)
    • 4.4.2.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 4.4.3. Atherectomy Systems Market estimates and forecast 2021 to 2033 (USD Million)
    • 4.4.3.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 4.4.4. Stents Market estimates and forecast 2021 to 2033 (USD Million)
    • 4.4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
    • 4.4.4.2. Self-Expanding Stents
      • 4.4.4.2.1. Market estimates and forecast 2021 to 2033 (USD Million)
    • 4.4.4.3. Balloon-Expandable Stents
      • 4.4.4.3.1. Market estimates and forecast 2021 to 2033 (USD Million)
    • 4.4.4.4. Covered Stent Grafts
      • 4.4.4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
    • 4.4.4.5. Bifurcated Aortic Stent Grafts
      • 4.4.4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 4.5. Surgical Devices
  • 4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 5. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Estimates & Trend Analysis

• 5.1. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Dashboard
• 5.2. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Movement Analysis
• 5.3. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Size & Forecasts and Trend Analysis, by Procedure, 2021 to 2033 (USD Million)
• 5.4. Endovascular Procedures
  • 5.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 5.4.2. Balloon Angioplasty Market estimates and forecast 2021 to 2033 (USD Million)
    • 5.4.2.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 5.4.3. Primary Stenting Market estimates and forecast 2021 to 2033 (USD Million)
    • 5.4.3.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 5.4.4. Kissing Stents Market estimates and forecast 2021 to 2033 (USD Million)
    • 5.4.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 5.4.5. Covered Stent Grafts Market estimates and forecast 2021 to 2033 (USD Million)
    • 5.4.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
  • 5.4.6. Endovascular Aortic Repair (EVAR) Market estimates and forecast 2021 to 2033 (USD Million)
    • 5.4.6.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.5. Hybrid Procedures
  • 5.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 5.6. Open Surgical Procedures
  • 5.6.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Estimates & Trend Analysis

• 6.1. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Dashboard
• 6.2. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Movement Analysis
• 6.3. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 6.5. Outpatient Facilities
  • 6.5.1. Market estimates and forecast 2021 to 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Regional Estimates & Trend Analysis by Country, Device Type, Procedure & End Use

• 7.1. Global Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Regional Dashboard
• 7.2. Market Size & Forecasts Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. U.S. market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Canada market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Regulatory framework/ reimbursement structure
    • 7.3.4.3. Competitive scenario
    • 7.3.4.4. Mexico market estimates and forecast, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. UK market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. Germany market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. France market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Italy market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Spain market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.4.8. Norway
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Norway market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.4.9. Denmark
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Regulatory framework/ reimbursement structure
    • 7.4.9.3. Competitive scenario
    • 7.4.9.4. Denmark market estimates and forecast, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Japan market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. India market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Australia market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Regulatory framework/ reimbursement structure
    • 7.5.7.3. Competitive scenario
    • 7.5.7.4. South Korea market estimates and forecast, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Brazil market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Argentina market estimates and forecast, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. Market Estimates and Forecasts 2021 to 2033 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.7.3. South Africa
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. South Africa market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. UAE market estimates and forecast, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Kuwait market estimates and forecast, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company analysis, 2025
  • 8.3.4. BD.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Bentley InnoMed
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Scitech Medical
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Abbott
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Boston Scientific Corporation
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. W. L. Gore & Associates, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Medtronic
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Cook
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Terumo Corporation
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. iVascular
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Getinge AB
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. Biotronik SE & Co KG
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives